Evidence map›Paper›PMID 38016739›Full record

ArticleSaudi medical journal2023

Application of arterial infusion ports in hepatic arterial infusion chemotherapy and embolization for advanced hepatocellular carcinoma.

Xinqiang Han, Peng Zhao, Xuemin Wang, Xiaoyu Tan, Yongzhen Zhang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xinqiang HanFrom the Department of Interventional Medicine and Vascular Surgery (Han, Zhang), from the Department of Gastroenterology (Wang), and from the First Clinical Medical College (Tan), Binzhou Medical University Hospital; from the Department of Minimally Invasive (Zhao), Interventional Therapy Center, Qingdao Municipal Hospital, Shandong, China.
Peng ZhaoFrom the Department of Interventional Medicine and Vascular Surgery (Han, Zhang), from the Department of Gastroenterology (Wang), and from the First Clinical Medical College (Tan), Binzhou Medical University Hospital; from the Department of Minimally Invasive (Zhao), Interventional Therapy Center, Qingdao Municipal Hospital, Shandong, China.
Xuemin WangFrom the Department of Interventional Medicine and Vascular Surgery (Han, Zhang), from the Department of Gastroenterology (Wang), and from the First Clinical Medical College (Tan), Binzhou Medical University Hospital; from the Department of Minimally Invasive (Zhao), Interventional Therapy Center, Qingdao Municipal Hospital, Shandong, China.
Xiaoyu TanFrom the Department of Interventional Medicine and Vascular Surgery (Han, Zhang), from the Department of Gastroenterology (Wang), and from the First Clinical Medical College (Tan), Binzhou Medical University Hospital; from the Department of Minimally Invasive (Zhao), Interventional Therapy Center, Qingdao Municipal Hospital, Shandong, China.
Yongzhen ZhangFrom the Department of Interventional Medicine and Vascular Surgery (Han, Zhang), from the Department of Gastroenterology (Wang), and from the First Clinical Medical College (Tan), Binzhou Medical University Hospital; from the Department of Minimally Invasive (Zhao), Interventional Therapy Center, Qingdao Municipal Hospital, Shandong, China.ORCID https://orcid.org/0009-0001-6376-9955
Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the safety and feasibility of subcutaneous implantable infusion ports in repeated hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) in China.

methodsA total of 237 patients who were clinically diagnosed with advanced HCC (CNLC III a/III b) in our hospitals from December 2020 to October 2022 were retrospectively analyzed. The approaches of HAIC were divided into 2 groups: arterial infusion port implantation (group A) and one-time femoral artery catheterization (group B) based on the physicians' suggestion and the patients' intention. The comfort level (evaluated with the General Comfort Questionnaire), complications and average inpatient expenditure were compared between the 2 groups.

results116 patients were finally enrolled in the study (group A: 69; group B: 47) and completed HAIC (FOLFOX-4 regimen) according to the dosing schedules (mean: 6±1 cycles). The comfort level of group A was greater than that of group B (

conclusionHepatic arterial infusion chemotherapy via arterial infusion ports for advanced HCC decreased complications and medical expenditures and improved patient comfort levels compared with indwelling catheters.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansInfusions, Intra-ArterialRetrospective StudiesTreatment Outcomearterial catheterizationhepatic arterial infusion chemotherapyhepatocellular carcinomaimplantable arterial infusion port

Identifiers

PMID38016739
PMCPMC10712783
OpenAlexW4389083328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.